🇺🇸 FDA
Pipeline program

Placebo for JNJ-95597528, JNJ-95597528

95597528ADM2001

Phase 2 small_molecule active

Quick answer

Placebo for JNJ-95597528, JNJ-95597528 for Moderate to Severe Atopic Dermatitis is a Phase 2 program (small_molecule) at Janssen-Cilag International N.V. with 1 ClinicalTrials.gov record(s).

Program details

Company
Janssen-Cilag International N.V.
Indication
Moderate to Severe Atopic Dermatitis
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials